Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Lianya Pharma Completes $62 Million Round for Hard-to-Make Generics

publication date: Feb 2, 2021

Nantong Lianya Pharma, a division of Novast, completed a $62 million funding that was led by Highlight Capital, with participation from Shiyu Investment. The company has 40 US-approved difficult-to-make generic drugs including over 30 hormone products and nine oral controlled-release drugs. Lianya is applying for China approvals of the drugs. One year ago, it raised $140 million in private equity led by Legend Capital. Founded in 2005, Lianya focuses on drug delivery/extended release formulations of generics. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022